A Two-Part Open-Label, Randomized, Sequential, Crossover, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of C-10355 and C-10358 in Healthy Volunteers, With a PK Comparison to Kalydeco
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Ivacaftor deuterated (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 05 Nov 2015 According to a Concert Pharmaceuticals media release, results from this trial were presented at the Cystic Fibrosis UK Trust Conference and the North American Cystic Fibrosis Conference.
- 22 Sep 2015 The data from this trial will be presented in the poster session at the North American Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.
- 22 Sep 2015 Results published in a Concert Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History